Altimmune (ALT) Cash from Investing Activities (2016 - 2025)
Altimmune (ALT) has disclosed Cash from Investing Activities for 16 consecutive years, with -$79.2 million as the latest value for Q4 2025.
- Quarterly Cash from Investing Activities fell 680.68% to -$79.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$132.5 million through Dec 2025, down 366.68% year-over-year, with the annual reading at -$132.5 million for FY2025, 366.68% down from the prior year.
- Cash from Investing Activities for Q4 2025 was -$79.2 million at Altimmune, up from -$149.3 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $101.1 million in Q2 2025, with the low at -$149.3 million in Q3 2025.
- Average Cash from Investing Activities over 5 years is -$6.7 million, with a median of $1.1 million recorded in 2022.
- The sharpest move saw Cash from Investing Activities skyrocketed 147900.0% in 2023, then tumbled 12553.79% in 2025.
- Over 5 years, Cash from Investing Activities stood at $24.9 million in 2021, then plummeted by 96.06% to $981000.0 in 2022, then tumbled by 911.31% to -$8.0 million in 2023, then soared by 271.28% to $13.6 million in 2024, then plummeted by 680.68% to -$79.2 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$79.2 million, -$149.3 million, and $101.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.